GSK Stock Analysis: Buy, Sell, or Hold?
GSK - GSK plc American Depositary Shares (Each representing two Ordinary Shares)
$52.41
0.45 (0.87%)
▲
5d:
+5.84%
30d:
+3.29%
90d:
+1.71%
BUY
HIGH Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 28, 2026
0d
Get Alerted When GSK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: GSK shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: GSK shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$71.62
Based on 6.1% avg growth
INTRINSIC VALUE TODAY
$44.47
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GSK is currently trading at $52.41, which is considered slightly high relative to its 30-day fair value range of $50.60 to $52.56. The stock's valuation (Forward PE: 10.2) is in line with its historical norms (10.4). Remarkably, the market is currently pricing in an annual earnings decline of 0.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, GSK is in a downtrend. The price is approaching resistance at $52.95. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GSK scores 72/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $58.08 (+10.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GSK is in a downtrend. The price is approaching resistance at $52.95. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GSK scores 72/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $58.08 (+10.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$50.60 -
$52.56
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.8%
All Signals
- BULLISH: Strong technical setup (72/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($58.08)
- BULLISH: Bottoming setup score 72/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$50.60 -
$52.56
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$48.86
Resistance Level
$52.95
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.20
Wall Street Target
$58.08
(+10.8%)
Revenue Growth (YoY)
5.3%
Earnings Growth (YoY)
-69.5%
Profit Margin
14.5%
Valuation Discount vs History
-0.7% cheaper
PE vs Historical
10.2 vs 10.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.7%
(market-implied from PE analysis)
1-Year Target
$52.04
(-1%)
2-Year Target
$51.68
(-1%)
3-Year Target
$51.32
(-2%)
3-Yr Target (if PE normalizes)
(PE: 10→10)
$52.30
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 8.1%)
$130.38
(+149%)
Base:
(SPY PE: 10.2, Growth: 8.1%)
$66.29
(+27%)
Bear:
(PE: 8.7, Growth: 8.1%)
$56.34
(+8%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 16.29 | Current EPS (TTM): $3.19
Bull Case
$92.03
(+76%)
Analyst growth 61.0%, PE expands to 17.9
Base Case
$83.66
(+60%)
Market implied 61.0%, PE stable at 16.3
Bear Case
$35.33
(-33%)
Severe decline -20.0%, PE contracts to 13.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.2 to 10.4
Stabilization Target:
$53.42
(+1.9%)
PE Expansion Potential:
+1.9%
Share & Embed Analysis
Last updated: August 22, 2026 8:33 PM ET
Data refreshes hourly during market hours. Next update: 9:33 PM
Data refreshes hourly during market hours. Next update: 9:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GSK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1311 | 37 SELL |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 34 SELL |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$276 | 41 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$238 | 42 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$384 | 38 SELL |
